{"id":11220,"date":"2020-09-17T00:00:00","date_gmt":"2020-09-17T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/"},"modified":"2025-08-19T08:28:19","modified_gmt":"2025-08-19T13:28:19","slug":"la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/","title":{"rendered":"LA POMALIDOMIDE, LE BORT\u00c9ZOMIB ET LA DEXAM\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE PR\u00c9C\u00c9DEMMENT TRAIT\u00c9S AVEC DU L\u00c9NALIDOMIDE (OPTIMISMM)"},"content":{"rendered":"<p>Dans l\u2019essai de phase 3 OPTIMISMM, la pomalidomide, le bort\u00e9zomib et la dexam\u00e9thasone (PVd) ont d\u00e9montr\u00e9 une efficacit\u00e9 sup\u00e9rieure \u00e0 celle du bort\u00e9zomib et de la dexam\u00e9thasone (Vd) chez les patients atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire ayant re\u00e7u un traitement ant\u00e9rieur de l\u00e9nalidomide, y compris les cas r\u00e9fractaires au l\u00e9nalidomide. Cette analyse a \u00e9valu\u00e9 les r\u00e9sultats chez les patients lors de la premi\u00e8re r\u00e9cidive (N = 226) en fonction du statut au l\u00e9nalidomide, de l\u2019exposition ant\u00e9rieure au bort\u00e9zomib et d\u2019une greffe ant\u00e9rieure de cellules souches.<\/p>\n<p>Consultez les d\u00e9tails de l\u2019\u00e9tude, <a href=\"https:\/\/www.nature.com\/articles\/s41375&nbsp;020\u201101021-3\" target=\"_blank\" rel=\"noopener\"><strong>ici<\/strong><\/a> (en anglais).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dans l\u2019essai de phase 3 OPTIMISMM, la pomalidomide, le bort\u00e9zomib et la dexam\u00e9thasone (PVd) ont d\u00e9montr\u00e9 une efficacit\u00e9 sup\u00e9rieure \u00e0 celle du bort\u00e9zomib et de la dexam\u00e9thasone (Vd) chez les patients atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire ayant re\u00e7u un traitement ant\u00e9rieur de l\u00e9nalidomide, y compris les cas r\u00e9fractaires au l\u00e9nalidomide. Cette analyse a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11220","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Dans l\u2019essai de phase 3 OPTIMISMM, la pomalidomide, le bort\u00e9zomib et la dexam\u00e9thasone (PVd) ont d\u00e9montr\u00e9 une efficacit\u00e9 sup\u00e9rieure \u00e0 celle du bort\u00e9zomib et de la dexam\u00e9thasone (Vd) chez les patients atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire ayant re\u00e7u un traitement ant\u00e9rieur de l\u00e9nalidomide, y compris les cas r\u00e9fractaires au l\u00e9nalidomide. Cette analyse a\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"LA POMALIDOMIDE, LE BORT\u00c9ZOMIB ET LA DEXAM\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE PR\u00c9C\u00c9DEMMENT TRAIT\u00c9S AVEC DU L\u00c9NALIDOMIDE (OPTIMISMM) | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"Dans l\u2019essai de phase 3 OPTIMISMM, la pomalidomide, le bort\u00e9zomib et la dexam\u00e9thasone (PVd) ont d\u00e9montr\u00e9 une efficacit\u00e9 sup\u00e9rieure \u00e0 celle du bort\u00e9zomib et de la dexam\u00e9thasone (Vd) chez les patients atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire ayant re\u00e7u un traitement ant\u00e9rieur de l\u00e9nalidomide, y compris les cas r\u00e9fractaires au l\u00e9nalidomide. Cette analyse a\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2020-09-17T05:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-19T13:28:19+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"LA POMALIDOMIDE, LE BORT\u00c9ZOMIB ET LA DEXAM\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE PR\u00c9C\u00c9DEMMENT TRAIT\u00c9S AVEC DU L\u00c9NALIDOMIDE (OPTIMISMM) | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Dans l\u2019essai de phase 3 OPTIMISMM, la pomalidomide, le bort\u00e9zomib et la dexam\u00e9thasone (PVd) ont d\u00e9montr\u00e9 une efficacit\u00e9 sup\u00e9rieure \u00e0 celle du bort\u00e9zomib et de la dexam\u00e9thasone (Vd) chez les patients atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire ayant re\u00e7u un traitement ant\u00e9rieur de l\u00e9nalidomide, y compris les cas r\u00e9fractaires au l\u00e9nalidomide. Cette analyse a\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/17\\\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\\\/#blogposting\",\"name\":\"LA POMALIDOMIDE, LE BORT\\u00c9ZOMIB ET LA DEXAM\\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE PR\\u00c9C\\u00c9DEMMENT TRAIT\\u00c9S AVEC DU L\\u00c9NALIDOMIDE (OPTIMISMM) | My\\u00e9lome Canada\",\"headline\":\"LA POMALIDOMIDE, LE BORT\\u00c9ZOMIB ET LA DEXAM\\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE PR\\u00c9C\\u00c9DEMMENT TRAIT\\u00c9S AVEC DU L\\u00c9NALIDOMIDE (OPTIMISMM)\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2020-09-17T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:19-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/17\\\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/17\\\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement, News &amp; Events, Nouvelles de My\\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/17\\\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"position\":2,\"name\":\"News &amp; Events\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"position\":3,\"name\":\"What's new at Myeloma Canada\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/17\\\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\\\/#listItem\",\"name\":\"LA POMALIDOMIDE, LE BORT\\u00c9ZOMIB ET LA DEXAM\\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE PR\\u00c9C\\u00c9DEMMENT TRAIT\\u00c9S AVEC DU L\\u00c9NALIDOMIDE (OPTIMISMM)\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/17\\\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\\\/#listItem\",\"position\":4,\"name\":\"LA POMALIDOMIDE, LE BORT\\u00c9ZOMIB ET LA DEXAM\\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE PR\\u00c9C\\u00c9DEMMENT TRAIT\\u00c9S AVEC DU L\\u00c9NALIDOMIDE (OPTIMISMM)\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/17\\\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/17\\\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/17\\\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/17\\\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/17\\\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\\\/\",\"name\":\"LA POMALIDOMIDE, LE BORT\\u00c9ZOMIB ET LA DEXAM\\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE PR\\u00c9C\\u00c9DEMMENT TRAIT\\u00c9S AVEC DU L\\u00c9NALIDOMIDE (OPTIMISMM) | My\\u00e9lome Canada\",\"description\":\"Dans l\\u2019essai de phase 3 OPTIMISMM, la pomalidomide, le bort\\u00e9zomib et la dexam\\u00e9thasone (PVd) ont d\\u00e9montr\\u00e9 une efficacit\\u00e9 sup\\u00e9rieure \\u00e0 celle du bort\\u00e9zomib et de la dexam\\u00e9thasone (Vd) chez les patients atteints d\\u2019un my\\u00e9lome multiple r\\u00e9cidivant ou r\\u00e9fractaire ayant re\\u00e7u un traitement ant\\u00e9rieur de l\\u00e9nalidomide, y compris les cas r\\u00e9fractaires au l\\u00e9nalidomide. Cette analyse a\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/09\\\/17\\\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2020-09-17T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:19-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"LA POMALIDOMIDE, LE BORT\u00c9ZOMIB ET LA DEXAM\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE PR\u00c9C\u00c9DEMMENT TRAIT\u00c9S AVEC DU L\u00c9NALIDOMIDE (OPTIMISMM) | My\u00e9lome Canada","description":"Dans l\u2019essai de phase 3 OPTIMISMM, la pomalidomide, le bort\u00e9zomib et la dexam\u00e9thasone (PVd) ont d\u00e9montr\u00e9 une efficacit\u00e9 sup\u00e9rieure \u00e0 celle du bort\u00e9zomib et de la dexam\u00e9thasone (Vd) chez les patients atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire ayant re\u00e7u un traitement ant\u00e9rieur de l\u00e9nalidomide, y compris les cas r\u00e9fractaires au l\u00e9nalidomide. Cette analyse a","canonical_url":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/#blogposting","name":"LA POMALIDOMIDE, LE BORT\u00c9ZOMIB ET LA DEXAM\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE PR\u00c9C\u00c9DEMMENT TRAIT\u00c9S AVEC DU L\u00c9NALIDOMIDE (OPTIMISMM) | My\u00e9lome Canada","headline":"LA POMALIDOMIDE, LE BORT\u00c9ZOMIB ET LA DEXAM\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE PR\u00c9C\u00c9DEMMENT TRAIT\u00c9S AVEC DU L\u00c9NALIDOMIDE (OPTIMISMM)","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2020-09-17T00:00:00-05:00","dateModified":"2025-08-19T08:28:19-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/#webpage"},"articleSection":"Actualit\u00e9s et \u00e9v\u00e9nement, News &amp; Events, Nouvelles de My\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","position":2,"name":"News &amp; Events","item":"https:\/\/myeloma.ca\/category\/news-events\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","position":3,"name":"What's new at Myeloma Canada","item":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/#listItem","name":"LA POMALIDOMIDE, LE BORT\u00c9ZOMIB ET LA DEXAM\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE PR\u00c9C\u00c9DEMMENT TRAIT\u00c9S AVEC DU L\u00c9NALIDOMIDE (OPTIMISMM)"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/#listItem","position":4,"name":"LA POMALIDOMIDE, LE BORT\u00c9ZOMIB ET LA DEXAM\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE PR\u00c9C\u00c9DEMMENT TRAIT\u00c9S AVEC DU L\u00c9NALIDOMIDE (OPTIMISMM)","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/","name":"LA POMALIDOMIDE, LE BORT\u00c9ZOMIB ET LA DEXAM\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE PR\u00c9C\u00c9DEMMENT TRAIT\u00c9S AVEC DU L\u00c9NALIDOMIDE (OPTIMISMM) | My\u00e9lome Canada","description":"Dans l\u2019essai de phase 3 OPTIMISMM, la pomalidomide, le bort\u00e9zomib et la dexam\u00e9thasone (PVd) ont d\u00e9montr\u00e9 une efficacit\u00e9 sup\u00e9rieure \u00e0 celle du bort\u00e9zomib et de la dexam\u00e9thasone (Vd) chez les patients atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire ayant re\u00e7u un traitement ant\u00e9rieur de l\u00e9nalidomide, y compris les cas r\u00e9fractaires au l\u00e9nalidomide. Cette analyse a","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2020-09-17T00:00:00-05:00","dateModified":"2025-08-19T08:28:19-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"LA POMALIDOMIDE, LE BORT\u00c9ZOMIB ET LA DEXAM\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE PR\u00c9C\u00c9DEMMENT TRAIT\u00c9S AVEC DU L\u00c9NALIDOMIDE (OPTIMISMM) | My\u00e9lome Canada","og:description":"Dans l\u2019essai de phase 3 OPTIMISMM, la pomalidomide, le bort\u00e9zomib et la dexam\u00e9thasone (PVd) ont d\u00e9montr\u00e9 une efficacit\u00e9 sup\u00e9rieure \u00e0 celle du bort\u00e9zomib et de la dexam\u00e9thasone (Vd) chez les patients atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire ayant re\u00e7u un traitement ant\u00e9rieur de l\u00e9nalidomide, y compris les cas r\u00e9fractaires au l\u00e9nalidomide. Cette analyse a","og:url":"https:\/\/myeloma.ca\/fr\/2020\/09\/17\/la-pomalidomide-le-bortezomib-et-la-dexamethasone-pour-traiter-les-patients-atteints-dun-myelome-multiple-precedemment-traites-avec-du-lenalidomide-optimismm\/","article:published_time":"2020-09-17T05:00:00+00:00","article:modified_time":"2025-08-19T13:28:19+00:00","twitter:card":"summary_large_image","twitter:title":"LA POMALIDOMIDE, LE BORT\u00c9ZOMIB ET LA DEXAM\u00c9THASONE POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE PR\u00c9C\u00c9DEMMENT TRAIT\u00c9S AVEC DU L\u00c9NALIDOMIDE (OPTIMISMM) | My\u00e9lome Canada","twitter:description":"Dans l\u2019essai de phase 3 OPTIMISMM, la pomalidomide, le bort\u00e9zomib et la dexam\u00e9thasone (PVd) ont d\u00e9montr\u00e9 une efficacit\u00e9 sup\u00e9rieure \u00e0 celle du bort\u00e9zomib et de la dexam\u00e9thasone (Vd) chez les patients atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire ayant re\u00e7u un traitement ant\u00e9rieur de l\u00e9nalidomide, y compris les cas r\u00e9fractaires au l\u00e9nalidomide. Cette analyse a"},"aioseo_meta_data":{"post_id":"11220","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-09-18 17:01:44","updated":"2026-04-30 07:22:12","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11220"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11220\/revisions"}],"predecessor-version":[{"id":31312,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11220\/revisions\/31312"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}